Interleukin-23: A key cytokine in inflammatory diseases

References

• Le Goff B, Blanchard F, Berthelot JM, Heymann D, Maugars Y. Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine. 2010;77:201–5.
   PubMed Web of Science ®Google Scholar
• Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O'Shea JJ. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev. 2004;202: 139–56.
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, . Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715–25.
   PubMed Web of Science ®Google Scholar
• Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, . Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 2009;60:738–49.
   PubMed Web of Science ®Google Scholar
• Collison LW, Vignali DA. Interleukin-35: odd one out or part of the family? Immunol Rev. 2008;226:248–62.
   PubMed Web of Science ®Google Scholar
• Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, . A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168:5699–708.
   PubMed Web of Science ®Google Scholar
• Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, . Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003;421:744–8.
   PubMed Web of Science ®Google Scholar
• Bastos KR, Marinho CR, Barboza R, Russo M, Alvarez JM, D'Imperio Lima MR. What kind of message does IL-12/IL-23 bring to macrophages and dendritic cells? Microbes Infect. 2004;6:630–6.
   PubMed Web of Science ®Google Scholar
• Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol. 2007;25:221–42.
   PubMed Web of Science ®Google Scholar
• Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, . Interleukin 17-producing CD4+effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123–32.
   PubMed Web of Science ®Google Scholar
• Boissier MC. Cell and cytokine imbalance in rheumatoid arthritis. Joint Bone Spine. 2010. DOI: 10.1016/j.jbspin. 2010.08.017.
   Google Scholar
• Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179–89.
   PubMed Web of Science ®Google Scholar
• Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol. 2008;9:641–9.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ, Konkel JE, . Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature. 2010; 467:967–71.
   PubMed Web of Science ®Google Scholar
• Buonocore S, Ahern PP, Uhlig HH, Ivanov II, Littman DR, Maloy KJ, . Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature. 2010;464: 1371–5.
   PubMed Web of Science ®Google Scholar
• Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity. 2009;31:331–41.
   PubMed Web of Science ®Google Scholar
• Ito Y, Usui T, Kobayashi S, Iguchi-Hashimoto M, Ito H, Yoshitomi H, . Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis. Arthritis Rheum. 2009;60:2294–303.
   PubMed Web of Science ®Google Scholar
• Cornelissen F, Mus AM, Asmawidjaja PS, van Hamburg JP, Tocker J, Lubberts E. Interleukin-23 is critical for full-blown expression of a non-autoimmune destructive arthritis and regulates interleukin-17A and RORgammat in gammadelta T cells. Arthritis Res Ther. 2009;11:R194.
   PubMed Web of Science ®Google Scholar
• Petermann F, Rothhammer V, Claussen MC, Haas JD, Blanco LR, Heink S, . Gammadelta T cells enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism. Immunity. 2010;33: 351–63.
   PubMed Web of Science ®Google Scholar
• Hedrick MN, Lonsdorf AS, Shirakawa AK, Richard Lee CC, Liao F, Singh SP, . CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest. 2009; 119:2317–29.
   PubMed Web of Science ®Google Scholar
• Ehlers S, Kaufmann SH. Infection, inflammation, and chronic diseases: consequences of a modern lifestyle. Trends Immunol. 2010;31:184–90.
   PubMed Web of Science ®Google Scholar
• Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, Stepankova R, . Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity. 2006;25:309–18.
   PubMed Web of Science ®Google Scholar
• Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, . Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med. 2004;351:2069–79.
   PubMed Web of Science ®Google Scholar
• Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, . Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 2007;132:2359–70.
   PubMed Web of Science ®Google Scholar
• Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, . A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314:1461–3.
   PubMed Web of Science ®Google Scholar
• Capon F, Di Meglio P, Szaub J, Prescott NJ, Dunster C, Baumber L, . Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet. 2007; 122:201–6.
   PubMed Web of Science ®Google Scholar
• Town T, Bai F, Wang T, Kaplan AT, Qian F, Montgomery RR, . Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing. Immunity. 2009;30:242–53.
   PubMed Web of Science ®Google Scholar
• Stetson DB, Medzhitov R. T helper 17 cells get the NOD. Immunity. 2007;27:546–8.
   PubMed Web of Science ®Google Scholar
• Tato CM, Cua DJ. Reconciling id, ego, and superego within interleukin-23. Immunol Rev. 2008;226:103–11.
   PubMed Web of Science ®Google Scholar
• Fantini MC, Pallone F. Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets. 2008;9:375–80.
   PubMed Web of Science ®Google Scholar
• Ljujic B, Radosavljevic G, Jovanovic I, Pavlovic S, Zdravkovic N, Milovanovic M, . Elevated serum level of IL-23 correlates with expression of VEGF in human colorectal carcinoma. Arch Med Res. 2010;41:182–9.
   PubMed Web of Science ®Google Scholar
• Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, . Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006;203:2673–82.
   PubMed Web of Science ®Google Scholar
• Kyttaris VC, Zhang Z, Kuchroo VK, Oukka M, Tsokos GC. Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. J Immunol. 2010;184:4605–9.
   PubMed Web of Science ®Google Scholar
• DeLay ML, Turner MJ, Klenk EI, Smith JA, Sowders DP, Colbert RA. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum. 2009;60:2633–43.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Bombardieri M, Principato A, Giardina A, Tripodo C, Porcasi R, . Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum. 2009;60:955–65.
   PubMed Web of Science ®Google Scholar
• Keshav S. Paneth cells: leukocyte-like mediators of innate immunity in the intestine. J Leukoc Biol. 2006;80:500–8.
   PubMed Web of Science ®Google Scholar
• Melis L, Vandooren B, Kruithof E, Jacques P, De Vos M, Mielants H, . Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis. 2010;69:618–23.
   PubMed Web of Science ®Google Scholar
• Moura RA, Cascao R, Perpetuo I, Canhao H, Sousa E, Rosario AF, . Cytokine profile in serum and synovial fluid of established rheumatoid arthritis patients (Poster). 7th International Congress on Autoimmunity; Ljubljana, Slovenia, 5–9 May 2010. PS11.
   Google Scholar
• Kim HR, Kim HS, Park MK, Cho ML, Lee SH, Kim HY. The clinical role of IL-23p19 in patients with rheumatoid arthritis. Scand J Rheumatol. 2007;36:259–64.
   PubMed Web of Science ®Google Scholar
• Hillyer P, Larche MJ, Bowman EP, McClanahan TK, de Waal Malefyt R, Schewitz LP, . Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1581–9.
   PubMed Web of Science ®Google Scholar
• Kageyama Y, Kobayashi H, Kato N. Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis. Mod Rheumatol. 2009;19:657–62.
   PubMed Web of Science ®Google Scholar
• Rueda B, Orozco G, Raya E, Fernandez-Sueiro JL, Mulero J, Blanco FJ, . The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis. Ann Rheum Dis. 2008;67:1451–4.
   PubMed Web of Science ®Google Scholar
• Hollis-Moffatt JE, Merriman ME, Rodger RA, Rowley KA, Chapman PT, Dalbeth N, . Evidence for association of an interleukin 23 receptor variant independent of the R381Q variant with rheumatoid arthritis. Ann Rheum Dis. 2009; 68:1340–4.
   PubMed Web of Science ®Google Scholar
• Safrany E, Hobor R, Jakab L, Tarr T, Csongei V, Jaromi L, . Interleukin-23 receptor gene variants in Hungarian systemic lupus erythematosus patients. Inflamm Res. 2010; 59:159–64.
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim I, Kim JO, Bae JS, Shin HD, Bae SC. No association between interleukin 23 receptor gene polymorphisms and systemic lupus erythematosus. Rheumatol Int. 2009;1:33–8.
   Google Scholar
• Li Y, Liang WB, Li C, Gao LB, Zhou B, Wang YY, . The association between interleukin-23 receptor gene polymorphisms and systemic lupus erythematosus. DNA Cell Biol. 2010;29:79–82.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, . Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008; 371:1665–74.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, . Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675–84.
   PubMed Web of Science ®Google Scholar
• Krulig E, Gordon KB. Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid. 2010;5:11–22.
   PubMedGoogle Scholar
• Liu J, Cao S, Herman LM, Ma X. Differential regulation of interleukin (IL)-12 p35 and p40 gene expression and interferon (IFN)-gamma-primed IL-12 production by IFN regulatory factor 1. J Exp Med. 2003;198:1265–76.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, . Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118–28.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, . A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008;135:1130–41.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, . Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633–40.
   PubMed Web of Science ®Google Scholar
• Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008;7:796–804.
   PubMed Web of Science ®Google Scholar
• Longbrake EE, Racke MK. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Rev Neurother. 2009;9:319–21.
   PubMed Web of Science ®Google Scholar
• Elliott M, Benson J, Blank M, Brodmerkel C, Baker D, Sharples KR, . Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann N Y Acad Sci. 2009;1182:97–110.
   PubMed Web of Science ®Google Scholar
• Lima XT, Abuabara K, Kimball AB, Lima HC. Briakinumab. Expert Opin Biol Ther. 2009;9:1107–13.
   PubMed Web of Science ®Google Scholar
• Gandhi M, Alwawi E, Gordon KB. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg. 2010;29:48–52.
   PubMed Web of Science ®Google Scholar
• Duvallet E, Ratsimendresy R, Assier E, Delavallée L, Bessis N, Zagury JF, . Active immunization against IL-23p19 improves collagen-induced-arthritis. Arthritis Rheum. 2009;10(Suppl):S1–2.
   Google Scholar
• Zhang Y, Ma X. Triptolide inhibits IL-12/IL-23 expression in APCs via CCAAT/enhancer-binding protein alpha. J Immunol. 2010;184:3866–77.
   PubMed Web of Science ®Google Scholar
• Yang Y, Weiner J, Liu Y, Smith AJ, Huss DJ, Winger R, . T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J Exp Med. 2009;206:1549–64.
   PubMed Web of Science ®Google Scholar
• Looney RJ. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs. 2010; 70:529–40.
   PubMed Web of Science ®Google Scholar